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Background: Health-related quality of life (HRQOL) is impaired in chronic obstructive pulmonary 
disease (COPD) patients, but determining factors for HRQOL are still not unequivocal. This study measures 
HRQOL among patients with COPD  and aims to determine factors associated with HRQOL. 
Methods: Data for cross-sectional analyses were obtained from the baseline of a cohort study. The 
study population includes adult COPD patients (disease duration ≥3 months), recruited from primary and 
secondary care settings in Germany, without acute psychiatric/neurologic disease (exception: affective/ 
anxiety disorders). HRQOL was assessed using the Short-Form 12 (SF-12) Health Survey Questionnaire, 
comprising a physical and mental component. Independent variables encompass socio-demographic, 
disease-specific, treatment-related and psychological factors. Multivariable linear regression analyses were 
conducted.
Results: In total, 206 COPD patients (60.7% male; mean age: 65.3 years) took part in the study. In 
multivariable analysis, the physical component score showed a significant negative association with the 
COPD Assessment Test (CAT) (P<0.001) and a higher total number of prescribed medications (P=0.001). A 
higher forced expiratory volume in 1 second (FEV1) value in percent predicted was significantly related to 
the physical component score in a positive manner (P=0.006). The mental component score was significantly 
associated with elevated patient-reported symptoms of anxiety (P=0.002) or depression (P<0.001), measured 
by the hospital anxiety and depression scale (HADS) in a negative way. Like for the physical component score 
(P<0.001), a worse CAT score was significantly associated with a lower mental component score (P=0.033). 
Conclusions: Focusing on patient reported outcomes and screening for depression and anxiety with 
potential successive treatment might be promising approaches to improve HRQOL in patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a 
common respiratory disease with life-time prevalences 
ranging from 1.2% (Malta) to 13.2% (Germany) in Europe 
(1,2). Globally, COPD is the third leading cause of death (3). 
COPD is usually a progressive disease which is characterized 
by an airflow limitation that is not fully reversible. Common 
symptoms are chronic cough, sputum production and 
dyspnea (4). Due to the ongoing demographic change and 
the higher prevalence with increasing age (2), the number 
of COPD patients is estimated to rise by 47% by the year 
2050 in Germany compared to numbers of 2007 (5). Since 
COPD has a major negative impact on the quality of life 
(QOL) and work productivity of COPD patients, it also 
poses a high burden on the economy in Germany (6). 
In order to fully display the whole burden of disease, 
many studies emphasize the importance of measuring QOL 
(7-10). Particularly health-related quality of life (HRQOL) 
is more and more investigated, meaning the part of QOL 
in general that is determined by health. In order to quantify 
the impact of the disease on patients, studies use both generic 
and disease-specific instruments (11). Generic instruments, 
such as the Short-Form 12 (SF-12) questionnaire (12) used 
in this study, measure overall HRQOL and provide an 
advantage compared to disease-specific questionnaires, as 
they allow comparisons with other diseases or the general 
population.
Compared to healthy persons, previous studies showed a 
significantly lower physical and mental HRQOL in patients 
with COPD (13,14). Therefore, one aim in the German 
guidelines for diagnosis and therapy of COPD is the 
improvement of both health status and QOL (15). 
Knowledge about determining factors of HRQOL is 
a mandatory prerequisite to improve it. Previous studies 
considered factors such as age, sex and co-morbidity (14,16) 
and revealed conflicting results (7). For instance, one study 
performed in the Netherlands found a higher age as a 
negative predicting factor for the health status of COPD 
patients (8) while another study from the USA found 
that younger patients had worse health status (17). Clear 
findings regarding influencing factors in previous studies 
exist for dyspnea, which seems to be the most important 
determinant of HRQOL in COPD patients (7,13). Based 
on strong evidence arising out of a systematic review, 
reduced HRQOL in COPD patients is negatively associated 
with depression and anxiety (18). So far, most studies have 
focused either on mild severity of disease using population 
based (13,19) or primary care based samples (8,20) or on 
severe cases only using data from secondary care settings 
(17,21). 
The objective of this study is to identify factors associated 
with generic HRQOL in patients with COPD recruited 
from both primary and secondary care settings in Germany. 
Methods
Study design and study population
The design of this study has been previously described in 
Böhmer et al. 2016 (22). In short the current study is based 
on data collected for a prospective patient cohort study 
investigating the influence of beliefs about medicines on 
adherence in patients with asthma or COPD. For the study 
presented here only patients with COPD are investigated. 
In order to cover a broad range of disease severity, patients 
were recruited from primary care and specialist practices 
as well as from in- and outpatients from hospital settings. 
The study sites are located in the region of Regensburg 
in the German federal state of Bavaria. The recruitment 
period for the baseline survey was from June 2013 until 
December 2014. Only patients who met the following 
inclusion criteria were enrolled in the study: COPD as main 
diagnosis ascertained by a physician, age ≥18 years; disease 
duration ≥3 months; no acute psychiatric/neurological 
disease (exception: depression or affective disorders) and 
sufficient knowledge of the German language. After a 
short introductory explanation all patients gave informed 
consent on-site before filling in the questionnaire. Data 
was collected both by using validated instruments and 
information from the patients’ medical records. Based on 
previous studies we determined a priori that we would 
investigate variables belonging to the domains patient 
characteristics, disease characteristics, treatment-related 
factors and psychological characteristics, as we aimed to 
take a broad perspective on variables likely influencing 
HRQOL. 
Definition of variables
HRQOL: dependent variable
A s  a  s h o r t  v e r s i o n  o f  t h e  S h o r t - F o r m  ( S F )  3 6 
questionnaire (23), the SF-12 questionnaire contains 
12 items in two scales: a physical (PCS-12) and mental 
health component scale (MCS-12) (12). The SF-12 
explains the majority of the variance (80–85%) of the 
768 Brandl et al. COPD: factors associated with generic HRQOL
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(2):766-775jtd.amegroups.com
SF-36. The scores for the two scales were calculated 
as described by Ware et al. (12). Response categories 
differ from binary to six response options (like “always” 
to “never”). A range of 0 (worst conceivable QOL) to 
100 (best conceivable QOL) is possible. For analysis, 
two summary scores were computed (12). The mean 
value of the German norm sample, which was used for 
standardization of scale scores in this study, is 50 in both 
the mental and physical component. 
Patient characteristics 
Sociodemographic data (age, gender and migration 
background), as well as information on estimated travelling 
time to the treating physician (in minutes) and the living 
situation (whether participants lived alone or not) were 
collected. Furthermore, the patients’ current smoking status 
was queried. 
Level of education was divided into two groups for this 
analysis: low education level (no school degree or school 
leaving diploma after 9 school years) and high education 
level (school diploma after 10 school years or university 
entrance diploma).
Characteristics of disease
COPD symptoms and functional status were measured 
using the COPD Assessment Test (CAT) (24,25). The 
CAT score has an overall range of 0–40 and comprises 
eight questions with five response categories each (0= no 
impairment). The overall CAT score can be derived as a 
sum of each single item score. A score of <10 indicates a low 
impact, a score between 10 and 20 a medium impact and a 
score of more than 20 indicates a high impact level (26). For 
this analysis, CAT was calculated as continuous variable. 
Higher scores indicate more symptoms and functional 
impairment. 
In addition, the duration of disease (in years) was 
obtained by asking for year of first diagnosis. Furthermore, 
we assessed the exacerbation history in the previous 
12 months as an important reflection of disease control and 
as a potential predictor of the course of disease (27). The 
latest forced expiratory volume in 1 second (FEV1) value in 
percent predicted (obtained from the medical record) was 
also taken into account. A classification of severity of airflow 
limitation in COPD patients is given from the “Global 
Initiative for chronic obstructive lung disease” (GOLD) (4) 
and is based on post bronchodilator FEV1 values. Patients 
are classified as mild COPD (GOLD1) if their FEV1 
is ≥80% predicted. A moderate COPD (GOLD2) includes 
FEV1 values between 50% and 80% predicted. If the 
patients’ FEV1 is between 30% and 50% predicted they 
are categorized as severe COPD or GOLD3. Very severe 
COPD (GOLD4) is present if FEV1 is less than 30% 
predicted. For analysis, only FEV1 in % predicted is taken 
into account, as GOLD status comprises the pulmonary 
function parameter and is therefore redundant.
Treatment of disease 
The presence of severe side effects and the number of 
medical consultations due to COPD during the last year 
were enquired in the questionnaire. Patients were also asked 
whether they had ever taken part in a rehabilitation measure 
owing to COPD. Valid information on the patient´s current 
medication was obtained from the medical record. For 
analysis the total number of prescribed drugs was taken into 
account.
Psychological influences
To measure symptoms of anxiety and depression the 
German version of the hospital anxiety and depression 
scale (HADS) was used (28). The total of 14 items was 
divided into two subscales (anxiety and depression scale) 
with 7 items each. Scores are constructed by summation, 
whereby both scores were classified into three categories: 
inconspicuous findings (≤7), marginally noticeable findings 
(8-10) and noticeable findings (≥11) (29). In Germany, the 
mean scores of the general population are 4.7 for women 
and 4.6 for men (HADS-D) and 5.0 and 4.4 (HADS-A), 
respectively (30). 
Statistical analysis
First, we performed a descriptive analysis. Continuous 
variables are reported as means (with minimum and 
maximum) and categorical variables as proportions. In a 
second step, we performed a univariate analysis in which 
all potential determinants were entered separately in 
linear regression models, with the physical and mental 
component summary scores (PCS-12/MCS-12) of the SF-12 
as dependent variables, respectively. Finally, all variables 
with a significant association in the univariate analysis were 
used as predictive variables in the multivariable model. For 
regression analysis, the level of significance was defined 
based on the confidence interval with an alpha error less than 
0.05. In case of missing data, the respective variables of these 
patients were not included in the analysis. All analyses were 
performed by using SPSS 22 (SPSS Inc., Chicago, USA).
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Results 
Characteristics of the study population
Data from 206 patients with COPD were analyzed. Of the 
seven study sites, three were practice and four were hospital 
settings. On average, COPD patients were 65 years old 
(SD =8.85) and approximately two thirds of them were 
of male sex. In total, 20.2% stated current smoking. On 
average, the diagnosis of COPD was made eight years 
(SD =7.92) before enrolment into the study. When 
categorizing the disease in four stages of disease severity, 
only a minority (4.7%) was grouped in the mildest stage 
GOLD 1. The largest group with 66 patients was GOLD 4 
(34.7%), closely followed by GOLD 3 (32.1%) and GOLD 
2 (28.4%). The number of exacerbations during the last 
year ranged from zero to 12, while about one third of the 
patients had more than two exacerbations (65 patients, 
34.3%). An even greater range was found in the number of 
doctor visits during the last year. The number ranged from 
zero to 52 (one a week), while nearly one fifth visited the 
doctor 10 times or more last year due to COPD problems. 
About one third of COPD patients were in an outpatient 
treatment at time of enrolment. Concerning the patients’ 
total number of prescribed medications, the variation was 
between one and 17 different medications, while the median 
number was 7. Just less than half of the patients had an 
inconspicuous score in the HADS-A score. The same goes 
for the depression score of the HADS, indicating that more 
than half of the patients reported symptoms of depression. 
The mean value of the physical and mental component scale 
was 31.8 and 38.0, respectively. Characteristics of the study 
population are displayed in Table 1. 
Univariate analysis 
In total, 194 patients could be included in univariate 
regression analysis. As shown in Table 2, mainly disease-
related, treatment-related and psychological factors were 
univariately associated with both component scales of the 
SF-12. Regarding socio-demographic factors, only female 
gender and migration background play a nearly significant 
or significant role in MCS-12 or PCS-12, respectively. 
Furthermore, the CAT score, the number of exacerbations 
during the last year, the total number of prescribed 
medications and reporting symptoms of depression or 
anxiety show a significant negative association with both 
scale scores of the SF-12. The FEV1 value in percent 
predicted was positively associated with both scores, PCS-12 
and MCS-12. Having taken part in a rehabilitation measure 
was associated with a significantly lower PCS score. The 
same is true for ever having experienced serious side effects 
due to medications taken for COPD treatment (Table 2). 
Multivariable analysis 
The multivariable model was built of variables which 
showed significant associations with HRQOL in univariate 
analysis. Looking at the final model, PCS-12 score 
showed a significant negative association with the CAT 
score. Furthermore, a higher total number of medications 
prescribed was significantly associated with PCS-12 score in 
a negative way. A higher FEV1 value in percent predicted 
was significantly related to PCS-12 score in a positive 
manner. These variables explained 57% of the variance in 
the PCS-12 variable in the final multivariable model.
Like with PCS-12, having a higher CAT score was 
associated with a significantly lower MCS-12 score. In 
contrast to PCS-12, MCS-12 score was significantly 
associated with elevated patient-reported symptoms of 
anxiety or depression in a negative way. More precisely, 
even reporting marginally noticeable symptoms of anxiety 
as well as reporting noticeable symptoms of anxiety or 
depression were associated with a reduced mental HRQOL. 
In total, 54% of the variance in the MCS-12 variable was 
explained by the just named variables (Table 3).
Sensitivity analyses were performed in order to 
investigate whether association patterns would differ 
between patients recruited from primary vs. secondary care. 
CAT score and FEV1 (in percent predicted) emerged as the 
strongest predictive factors in both subsamples and were, 
significantly related to PCS-12 score in both groups. For 
MCS-12 score, a noticeable HADS-D remained the factor 
most strongly associated in both groups (data not shown). 
Discussion
Principal findings
This cross-sectional study, investigating determinants of 
generic HRQOL in COPD patients, indicates a lower PCS-
12 score and MCS-12 score in COPD patients compared 
to the German norm population (31). Regarding significant 
determinants, the CAT score was the only factor associated 
with both the physical and mental component of the SF-12. 
Lung function and total number of medications, both of 
which reflect disease severity, were related to worse physical 
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Table 1 Characteristics of the study population (N=206)
Characteristic N Mean value/absolute number [Minimum; maximum] & SD or %
Socio-demographic & lifestyle factors
Age 206 65.30 [41; 93]; 8.85
Male gender 206 125 60.7%
Education level 195
Low 145 74.4%
High 50 25.6%
Living alone 202 45 22.3%
Having migration background 202 10 5%
Estimated travelling time to practitioner (minutes) 198 30.1 [5; 120]; 18.05
Current smokers 198 40 20.2%
Disease-specific factors
FEV1 in % predicted 143 46.89 [4.03; 109.4]; 21.44
GOLD 1 190 9 4.7%
GOLD 2 190 54 28.4%
GOLD 3 190 61 32.1%
GOLD 4 190 66 34.7%
CAT 192 23.26 [5; 39]; 7.20
Number of exacerbations 189 2.06 [0; 12]; 2.10
Duration of disease 190 8.44 [0; 54]; 7.92
Treatment related factors
Total number of medications 206 6.9 [1; 17]; 3.97
Serious side effects 198 48 24.2%
Number of doctor visits (1 year) 194 6.30 [0; 52]; 6.41
Inpatient treatment 206 143 69.4%
Rehabilitation 200 95 47.5%
Psychological factors
HADS-A 200
Inconspicuous 93 46.5%
Marginally noticeable 51 25.5%
Noticeable 56 28.0%
HADS-D 194
Inconspicuous 89 45.9%
Marginally noticeable 38 19.6%
Noticeable 67 34.5%
Health-related quality of life 
SF-12: mental component scale 194 37.99 [9.81; 69.66]; 14.3
SF-12: physical component scale 194 31.78 [11.91; 57.76]; 9.71
SD, standard deviation; CAT, COPD assessment test; FEV1, forced expiratory volume in 1 second; HADS-A, hospital anxiety and 
depression scale—anxiety scale; HADS-D, HADS—depression scale; SF-12, Short-Form 12; MCS-12, mental component of the SF-12; 
PCS-12, physical component of the SF-12.
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HRQOL. Reporting symptoms of anxiety or depression 
show the strongest associations with MCS-12 score. 
Disease-specific factors
CAT 
The CAT has been developed as simple and reliable 
measure of health status in COPD patients (24) and can 
therefore be considered as a measure of COPD specific 
QOL. As far as we know the relationship of CAT with 
generic HRQOL has not been investigated before. If one 
takes a closer look at the content of the CAT, it becomes 
apparent that it enquires about symptoms (cough, phlegm/
mucus, chest tightness, dyspnea) and functional limitations 
Table 2 Associations between PCS-12/MCS-12 and potential determinants in COPD patients: results of univariate linear regression analysis
Determinants
PCS-12 MCS-12 
B β P B β P
Disease-specific-factors
CAT −0.76 −0.58 <0.001 −0.96 −0.49 <0.001
FEV1 % predicted 0.27 0.56 <0.001 0.20 0.30 <0.001
Number of exacerbations −1.84 −0.40 <0.001 −2.75 −0.40 <0.001
Disease duration (years) −0.03 −0.03 0.740 −0.10 −0.05 0.467
Socio-demographic factors
Age (years) 0.05 0.05 0.487 0.02 0.01 0.844
Female gender −0.73 −0.04 0.611 −3.86 −0.13 0.068
Having Migration backgrounda 7.63 0.17 0.019 −1.26 −0.02 0.797
Living aloneb −1.42 −0.06 0.392 −1.83 −0.05 0.462
Estimated travelling time to practitioner (minutes) −0.02 −0.04 0.593 −0.05 −0.07 0.351
High education levelc −0.46 −0.02 0.775 2.27 0.07 0.349
Smoking 0.18 0.01 0.919 −1.35 −0.04 0.602
Treatment related factors
Total number of medications −1.11 −0.46 <0.001 −1.06 −0.30 <0.001
Serious side effects due to COPD medicationd −2.90 −0.13 0.080 −0.99 −0.03 0.690
Number of doctor visits (last year) −0.18 −0.12 0.103 −0.24 −0.11  0.134
Participation at rehabilitation measures −2.92 −0.15 0.036 −0.46 −0.02 0.826
Psychological factors
HADS-Ae
Marginally noticeable −1.40 −0.06 0.409 −13.83 −0.42 <0.001
Noticeable −4.47 −0.21 0.008 −20.12 -0.62 <0.001
HADS-Df
Marginally noticeable −5.52 −0.23 0.002 −10.69 −0.30 <0.001
Noticeable −8.07 −0.40 <0.001 −20.62 −0.68 <0.001
a, no migration background; b, living not alone; c, low education level; d, no serious side effects; e, inconspicuous HADS-A; f, inconspicuous 
HADS-D. CAT, COPD assessment test; FEV1, forced expiratory volume in 1 second; HADS-A, hospital anxiety and depression scale—
anxiety scale; HADS-D, HADS–depression scale; SF-12, Short-Form 12; MCS-12, mental component of the SF-12; PCS-12, physical 
component of the SF-12.
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(sleep disorders, domestic work, energy, confident leaving 
home). Therefore, an association with physical HRQOL 
was to be expected. However, the finding of a significant 
negative association between CAT and mental HRQOL is 
noteworthy and moreover the only significant relationship 
besides the association between MCS-12 score with 
psychological factors. 
FEV1 
FEV1 is the most commonly used way to express functional 
impairment. Although it is quite difficult to compare 
or summarize results, due to heterogeneity in outcome 
measures and instruments used, our results are comparable 
to previous studies (32). According to results of Garrido 
et al., who found a higher correlation between FEV1 and 
PCS-12 score (20), predicted FEV1% was only significantly 
associated with PCS-12 score in the multivariable analysis of 
this study. Bentsen et al. demonstrated that subjective health 
status in COPD patients is determined more by symptoms, 
particular breathlessness as well as anxiety and depression, 
than demographics or physiological variables like predicted 
FEV1% (33). In a study of Janson et al. (13) lower FEV1 
was associated with a lower PCS-12 score, but there was no 
significant association between FEV1 and the mental part 
of QOL. The strong association in our univariate analysis is 
possibly explainable by the high number of severe and even 
very severe COPD patients in our study population. Often 
patients with COPD stage IV are underrepresented in 
studies due to time consuming test batteries which impose a 
burden to patients. In a study of Pereira et al. (34) 57.1% of 
patients were classified as having severe or extremely severe 
COPD. In this study, FEV1 was the parameter that best 
correlated with the St Georges Respiratory Questionnaire 
(SGRQ), another disease-specific measure of HRQOL 
for chronic respiratory illness, total score and the only 
respiratory function parameter that correlated with PCS-36 
score. 
Treatment related factors
In our study, poorer physical HRQOL was associated with 
a higher number of total medications in multivariable 
analysis. In reviewing the literature, a study with 611 
COPD patients (43.7% with COPD GOLD III) found that 
patients who took two or more medications to treat their 
COPD compared to patients without any medication had 
a clinically relevant decrease in their HRQOL measured 
with SGRQ (35). Furthermore, Miravitlles et al. showed in 
Table 3 Multivariable analysis: regression coefficients (B, β) and 95% confidence intervals (CI) for the physical and mental part of the SF-12 
separately [COPD patients (n=194)]
Independent variables
PCS-12 (R2=0.57) MCS-12 (R²=0.54)
B β 95% CI (B) P B β 95% CI (B) P
Constant 43.825 36.29; 51.36 <0.001 57.33 47.10; 67.55 <0.001
CAT −0.54 −0.40 −0.76; −0.31 <0.001 −0.34 −0.19 −0.65; −0.03 0.033
FEV1 in % predicted 0.11 0.23 0.03; 0.18 0.006 0.006 0.009 −0.10; 0.11 0.908
Number of exacerbations during 
last year
−0.04 −0.01 −0.81; 0.74 0.925 −0.63 −0.01 –1.72; 0.46 0.256
Migration background a 3.45 0.06 −4.00; 10.90 0.361
Total number of medications −0.74 −0.28 −1.15; −0.33 0.001 −0.05 −0.01 −0.62; 0.53 0.876
Rehabilitation measure 1.41 0.07 −1.34; 4.16 0.312
HADS-Ab marginally noticeable −7.74 −2.24 −12.49; −2.98 0.002
HADS-Ab noticeable 1.84 0.08 −1.87; 5.56 0.327 −9.01 −2.28 −14.72; −3.30 0.002
HADS-Dc marginally noticeable −0.83 −0.03 −4.62; 2.95 0.663 −4.02 −0.11 −9.34; 1.31 0.138
HADS-Dc noticeable −2.30 −0.10 −6.46; 1.86 0.275 −11.12 −0.36 −17.07; −5.17 <0.001
a, no migration background; b, inconspicuous HADS-A; c, inconspicuous HADS-D. CAT, COPD assessment test; FEV1, forced expiratory 
volume in 1 second; HADS-A, Hospital Anxiety and Depression Scale—anxiety scale; HADS-D, HADS–depression scale; MCS-12, mental 
component of the Short-Form 12 Questionnaire (SF-12); PCS-12, physical component of the SF-12.
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a cross-sectional study with 441 COPD patients, that the 
PCS-12 score was significantly associated with the number 
of different drugs (36). Since in our study no differentiation 
was made between medications for treating COPD and 
other medications, a direct comparison with these studies 
is not possible. However, a similar trend can be observed. 
Since there is only a significant association with the 
physical QOL, the total number of medications taken could 
potentially represent a proxy measure for the number of 
comorbidities. 
Psychological factors
In this study, about one third of the patients reported a 
noticeable amount of depressive symptoms and about 20 % 
were grouped as having marginally noticeable depressive 
symptoms. Having marginally noticeable symptoms of 
anxiety is true for about 25% in our study. Our finding 
is comparable to the prevalence of clinically significant 
depressive symptoms in COPD patients revealed in a meta-
analysis study by Zhang et al. (37). Together HADS-A and 
HADS-D explain the majority of variance in the mental 
component of HRQOL in our study. In contrast to the 
significantly negative associations between HADS and 
MCS-12 score, our study found no association between 
the different categories of the HADS and the physical 
component of the SF-12 questionnaire. A review and 
meta-analysis of Tsiligianni et al. (7) has shown a persisting 
association between depression or rather anxiety with 
QOL, when using different questionnaires. Looking at 
the SF-36, the long form of the SF-12 questionnaire used 
in our study, a cross-sectional study revealed that COPD 
patients without significant depressive symptoms had 
significantly higher scores in all sub-scales of the SF-36 
compared to those with depressive symptoms (38). Even 
across multiple study designs the relationship between 
anxiety and depression with HRQOL remains the same (39). 
Moreover, when depression and anxiety are considered 
as comorbidities, a strong association with HRQOL can 
be found in literature (18). A clear association between 
depressive or anxious symptoms and HRQOL can therefore 
be assumed. However, it has to be noted, that both HADS 
and MCS-12 tap into related constructs which means that a 
correlation can be expected to some extent.
Strengths and weaknesses
To interpret the findings of the study correctly, some 
limitations should be acknowledged. Due to the cross-
sectional design of our study, no causal relationships 
could be revealed as we are unable to disentangle the time 
sequence of events. Furthermore, HRQOL was obtained 
as a self-reported outcome, which means that for example 
daily sensitivities like stress or bad mood may influence 
the answers as there are included retrospective questions. 
However, self-reported outcome measures are considered 
important measuring tools in clinical research when it 
comes to HRQOL (40). Even if there was no random 
selection of participating physicians, we aimed to cover a 
wide range of different recruitment sites in order to get a 
most generalizable COPD population. Despite the attempt 
we made to recruit a broad range of severities from different 
recruitment sites, we did end up with a sample that has a 
higher proportion of severe and very severe stages of COPD 
compared to the general COPD population in Europe (41). 
A further strength is the broad approach with different 
spheres of influence analyzed, as living with COPD is 
complex and there are various domains that possibly 
affect HRQOL. Furthermore, the use of standardized and 
validated measurement instruments for our main outcome 
and most of our independent variables is a strength of our 
study.
Conclusions
Depending on the component of QOL, HRQOL is 
associated with a number of factors. The strongest of which 
are COPD-specific HRQOL for generic physical HRQOL 
and reporting symptoms of depression and/or anxiety for 
generic mental HRQOL. In clinical practice screening for 
depression and anxiety and referring potentially affected 
patients to psychiatric assessment may be promising 
approaches to enhance the QOL of COPD patients. 
Furthermore, the conduct of robust interventional studies is 
warranted. 
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